July 11, 2008 - The court issued an order that any complaints filed within the consolidated complaint be dismissed with prejudice in their entirety.
June 6, 2008 - The court granted the defendants motions to dismiss without prejudice.

February 29, 2008 - The defendants filed motions to dismiss.

January 18, 2008 - The lead plaintiff filed a consolidated complaint.

November 27, 2007 - The lead plaintiff and lead counsel were appointed.

October 23, 2007 - A lead plaintiff motion was filed.

September 13, 2007 - Another investor filed a complaint

August 24, 2007 - An investor in shares of Advanced Medical Optics Inc (NYSE: EYE) filed a complaint in the U.S. District Court for the Central District of California against Advanced Medical Optics Inc over alleged violations of Federal Securities Laws in connection with certain allegedly false and misleading statements made between January 4, 2007 and May 25, 2007.

The complaint charges Advanced Medical Optics Inc and certain of its officers and directors with violations of the Securities Exchange Act of 1934. Advanced Medical Optics Inc is engaged in the development, manufacture and marketing of medical devices for the eye.

Specifically, the complaint alleges that defendants violated the Federal Securities Laws by disseminating false and misleading statements to the investing public and concealing negative information, making it impossible for shareholders to gain a meaningful or realistic understanding of the risks and long-term market success of Advanced Medical Optics Inc’s profitable contact lens solution, Complete MoisturePlus™ Multipurpose Solution. As a result of defendants’ false statements, Advanced Medical Optics Inc (NYSE: EYE) stock traded at inflated levels between January 4, 2007 and May 25, 2007, during which time Advanced Medical Optics Inc’s top officers and directors were able to reap more than $6.8 million in insider trading proceeds.

According to the complaint, in November 2006, Advanced Medical Optics Inc had announced a voluntary recall of certain eye care product lots and the related manufacturing capacity constraints caused by a production-line issue at its manufacturing plant in China. The plaintiff further alleges the defendants had successfully convinced the market that problems with Complete were in the past. Then on May 25, 2007, after the market closed, Advanced Medical Optics Inc issued a press release announcing the voluntary recall of Complete due to the risk of corneal infection that was linked to the use of Complete. On this news, Advanced Medical Optics Inc (NYSE: EYE) stock collapsed, dropping $5.51 per share on volume of 16.2 million shares.